Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Zhang, Xulong ^a,b,c   Xiao, Weihua ^c   Wang, Lihua ^a   Tian, Zhigang ^c   Zhang, Jian ^a  

^a SHANDONG UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; LUCIFERASE; MULTIDRUG RESISTANCE PROTEIN 1; OLIGODEOXYNUCLEOTIDE; STAT3 PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; OLIGODEOXYRIBONUCLEOTIDE;

ARTICLE; BINDING SITE; CELL STRAIN K 562; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MDR1 GENE; MYELOID LEUKEMIA; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; DRUG EFFECT; DRUG RESISTANCE; GENE; GENETICS; LEUKEMIA; METABOLISM; MULTIDRUG RESISTANCE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIBIOTICS, ANTINEOPLASTIC; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, MDR; HUMANS; K562 CELLS; LEUKEMIA; OLIGODEOXYRIBONUCLEOTIDES; P-GLYCOPROTEIN; STAT3 TRANSCRIPTION FACTOR;

EID: 79958161210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020965     Document Type: Article

References (31)

1. Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, et al. (2007) Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 86: 166-173.
2. Higgins CF, (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446: 749-757.
3. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, et al. (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10: 7896-7902.
4. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T, (2005) MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 128: 324-332.
5. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, et al. (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88: 809-816.
6. Yu H, Jove R, (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105.
7. Zhang X, Zhang J, Wang L, Wei H, Tian Z, (2007) Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 7: 149.
8. Zhang X, Zhang J, Wei H, Tian Z, (2007) STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep 17: 1377-1382.
9. George JA, Chen T, Taylor CC, (2005) SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res 65: 10381-10388.
10. Xi S, Gooding WE, Grandis JR, (2005) In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24: 970-979.
11. Lau CK, Yang ZF, Lam SP, Lam CT, Ngai P, et al. (2007) Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther 6: 1900-1907.
12. Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, et al. (2004) Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res 64: 1843-1852.
13. Zhou J, Ong CN, Hur GM, Shen HM, (2010) Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem Pharmacol 79: 1242-1250.
14. Ikuta K, Takemura K, Kihara M, Nishimura M, Ueda N, et al. (2005) Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Oncol Rep 13: 217-222.
15. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, et al. (2006) Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12: 5055-5063.
16. Bourguignon LY, Peyrollier K, Xia W, Gilad E, (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283: 17635-17651.
17. Yang CZ, Luan FJ, Xiong DS, Liu BR, Xu YF, et al. (1995) Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin. Zhongguo Yao Li Xue Bao 16: 333-337.
18. Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J, (2003) Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Cancer 106: 108-115.
19. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, et al. (2003) Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 100: 4138-4143.
20. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, et al. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279.
21. Hodge DR, Li D, Qi SM, Farrar WL, (2002) IL-6 induces expression of the Fli-1 proto-oncogene via STAT3. Biochem Biophys Res Commun 292: 287-291.
22. Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB, et al. (1995) Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci U S A 92: 3041-3045.
23. Sun X, Zhang J, Wang L, Tian Z, (2008) Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262: 201-213.
24. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, et al. (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97.
25. Wartenberg M, Gronczynska S, Bekhite MM, Saric T, Niedermeier W, et al. (2005) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int J Cancer 113: 229-240.
26. Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, et al. (2008) Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 7: 670-678.
27. Vilgelm A, Wei JX, Piazuelo MB, Washington MK, Prassolov V, et al. (2008) DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene 27: 2170-2176.
28. Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, et al. (2010) Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 29: 6314-6322.
29. Zhang X, Liu P, Zhang B, Wang A, Yang M, (2010) Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet 197: 46-53.
30. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, et al. (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15: 283-293.
31. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, et al. (2008) Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7: 3169-3175.